The Association of Plasma Osmolarity With No-Reflow in Patients With ST-Segment Elevation Myocardial Infarction: A

Faraz Ahmad1, Ahmad Usman2,3, Aneela Afreen3

  • 1Cardiology, Shalamar Hospital, Lahore, PAK.

Cureus
|July 23, 2025
PubMed

Insights

High plasma osmolarity is linked to a greater risk of the no-reflow phenomenon after primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) patients. This finding suggests osmolarity could aid in early risk assessment for better treatment outcomes.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Clinical Biochemistry

Background:

  • The no-reflow phenomenon is a significant complication post-primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).
  • It leads to impaired myocardial reperfusion and poorer patient outcomes.
  • Identifying predictors for no-reflow is crucial for improving treatment strategies.

Purpose of the Study:

  • To investigate the association between admission plasma osmolarity and the incidence of no-reflow.
  • To determine if plasma osmolarity can serve as an independent predictor of no-reflow in STEMI patients undergoing primary PCI.

Main Methods:

  • Retrospective cohort study involving 486 STEMI patients undergoing primary PCI.
  • Data collected from Shalamar Hospital, Lahore, Pakistan (February 2022 - February 2025).
  • Inclusion criteria: age ≥ 18 years, confirmed STEMI diagnosis, and primary PCI.

Main Results:

  • High plasma osmolarity (>295 mOsm/L) was significantly associated with a higher no-reflow incidence (31.1%) compared to normal (13.4%) and low (9.2%) groups (p < 0.001).
  • High plasma osmolarity independently predicted an increased risk of no-reflow (adjusted odds ratio 2.94; 95% CI: 1.61-5.38; p < 0.001).

Conclusions:

  • Elevated plasma osmolarity is an independent predictor of the no-reflow phenomenon in STEMI patients undergoing primary PCI.
  • Routine plasma osmolarity assessment may facilitate early risk stratification.
  • This could inform personalized management strategies to enhance reperfusion outcomes.

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
80
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
47
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
341